Previously, using a large cohort of 98 de novo AML patients with KMT2A-PTD, we reported that 90.8% of patients had at least one additional gene mutation including FLT3-ITD (44.9%), DNMT3A (32.7%), RUNX1 (23.5%) and TET2 (18.4%) mutations12. Here, FLT3 is linked to acute myeloid leukemia.